Brentuximab
Product Specifications
UNSPSC Description
Brentuximab is a monoclonal antibody targeting CD30. Brentuximab is conjugated with monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107), which can induce apoptosis in primary effusion lymphoma cells. Brentuximab vedotin exhibits antitumor activity with an IC50 of 10 nM against human CD30+ cancer cells[1][2][3].
Target Antigen
ADC Antibody; TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Antibody-drug Conjugate/ADC Related;Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/brentuximab.html
Purity
99.64
Solubility
10 mM in DMSO
Smiles
[Brentuximab]
References & Citations
[1]Bhatt S, et al. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood. 2013 Aug 15;122(7):1233-42. |[2]Chen R W, et al. Inhibition of MDR1 overcomes brentuximab vedotin resistance in Hodgkin lymphoma cell line model and is synergistic with brentuximab vedotin in mouse xenograft model[J]. Blood, 2016, 128(22): 752.|[3]Wang Z, et al. CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model. FEBS Open Bio. 2023 Jul;13(7):1309-1319.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99151/Brentuximab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99151/Brentuximab-SDS-MedChemExpress.pdf
Clinical Information
Phase 4
CAS Number
2088770-90-3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items